Samsung Bioepis Announces Three-year Follow-up Data for Biosimilar ONTRUZANT® (trastuzumab) in Early or Locally Advanced HER2-positive Breast Cancer
Samsung Bioepis Co., Ltd. today announced findings of a three-year follow-up study comparing biosimilar ONTRUZANT® (trastuzumab) and reference medicine trastuzumab in early or locally advanced HER2-positive breast cancer. The data, which show comparable overall survival and cardiac safety, were presented today at the 16th St. Gallen International Breast Cancer Conference 2019 taking place in Vienna, Austria.
“With the development of our biosimilar trastuzumab, we aimed to make one of the mainstays of modern cancer therapy more accessible for more people more quickly, and these long-term data underline the importance of that aim,” said Chul Kim, Senior Vice President and Head of Clinical Sciences Division, Samsung Bioepis. “We are committed to increasing access to high-quality, life-changing oncology medicines through the development of biosimilars to address some of oncology’s most pressing challenges.”
Participants enrolled in an initial Phase III study received eight cycles of the biosimilar trastuzumab or the reference medicine concurrently with chemotherapy in the neoadjuvant setting. Following surgery, they received additional 10 cycles of the biosimilar trastuzumab or the reference medicine. After completion of therapy, 367 of these participants (186 in the biosimilar trastuzumab group and 181 in the reference medicine group) were enrolled in the follow-up study. Median follow-up from initiation of study treatment was 40.8 months in the biosimilar trastuzumab group and 40.5 months in the reference medicine group.
Overall survival was 97% in the biosimilar trastuzumab group and 93.6% in the reference medicine group (HR 0.39, 95% CI, 0.14-1.12). Event-free survival was 92.5% in the biosimilar trastuzumab group and 86.3% in the reference medicine group (HR 0.49, 95% CI, 0.26-0.91). The incidence of cardiac events was rare for both treatment groups throughout the three-year follow-up period. There were three cases of asymptomatic significant left ventricular ejection fraction (LVEF) decrease (biosimilar trastuzumab, n=1; reference medicine, n=2), with all patients recovering with LVEF ≥ 50%. There were no cases of symptomatic congestive heart failure, cardiac death or other significant cardiac conditions reported in either group.
The poster of this study will be exhibited at the 16th St. Gallen International Breast Cancer Conference 2019, as follows:
- [P156] 3-YEAR FOLLOW-UP OF A PHASE III STUDY COMPARING SB3 (TRASTUZUMB BIOSIMILAR) AND REFERENCE TRASTUZUMAB IN HER2 POSITIVE EARLY OR LOCALLY ADVANCED BREAST CANCER IN NEOADJUVANT SETTING [POSTER SESSION I, MARCH 21, 2019]
ONTRUZANT® (trastuzumab) 150 mg was granted the European
Commission (EC) Marketing Authorization in November 2017 and was
approved by the U.S. Food and Drug Administration in January 2019. In
February 2019, the European Medicines Agency’s (EMA) Committee for
Medicinal Products for Human Use (CHMP) adopted a positive opinion for a
420 mg vial presentation of ONTRUZANT®.iii With
the adoption of CHMP’s positive opinion for ONTRUZANT® 420 mg
vial presentation, ONTRUZANT® will be available in two vial
sizes in Europe, providing clinics with greater convenience and
flexibility than the 150 mg vial presentation alone.
About Samsung Bioepis Co., Ltd.
Established in 2012, Samsung Bioepis is a biopharmaceutical company committed to realizing healthcare that is accessible to everyone. Through innovations in product development and a firm commitment to quality, Samsung Bioepis aims to become the world's leading biopharmaceutical company. Samsung Bioepis continues to advance a broad pipeline of biosimilar candidates that cover a spectrum of therapeutic areas, including immunology, oncology and ophthalmology. Samsung Bioepis is a joint venture between Samsung BioLogics and Biogen. For more information, please visit: www.samsungbioepis.com.
i HERCEPTIN® is a registered trademark of Genentech Inc.
ii Pivot, X et al. 2019. 3-year Follow-up of a Phase III Study Comparing SB3 (trastuzumab biosimilar) and Reference Trastuzumab in HER2 Positive Early or Locally Advanced Breast Cancer in Neoadjuvant Setting. St Gallen International Breast Cancer Conference, Vienna, Austria, 20-23 March 2019. [P156 Poster Session I, March 21, 2019]
iii European Medicines Agency – Committee for Medicinal Products for Human Use (CHMP). Final agenda for the meeting on 25-28 February 2019. Available at: https://www.ema.europa.eu/documents/agenda/agenda-chmp-agenda-25-28-february-2019_en.pdf . Last accessed February 2019.
Om Business Wire
(c) 2018 Business Wire, Inc., All rights reserved.
Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.
Følg saker fra Business Wire
Registrer deg med din epostadresse under for å få de nyeste sakene fra Business Wire på epost fortløpende. Du kan melde deg av når som helst.
Siste saker fra Business Wire
AqVida and Phyton Biotech Receive Approval from European Directorate of Quality Medicines for AqVida’s Cancer-fighting Paclitaxel Injectable Finished Dosage Formulation18.4.2019 10:00:00 CEST | Pressemelding
Phyton Biotech, a German/North American Plant Cell Fermentation (PCF®) technology company, and AqVida, a German oncology Finished Dosage Formulation (FDF) manufacturer, are pleased to announce today that they have received European approval from the EDQM (European Directorate of Quality Medicines) for AqVida’s paclitaxel injectable FDF. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20190418005161/en/ Phyton Biotech is the world’s leading manufacturer of paclitaxel active pharmaceutical ingredient (API), utilizing its prorprietary PCF® technology process. Under the strategic partnership with AqVida, Phyton Biotech will be the exclusive supplier of paclitaxel API for AqVida’s Taxol generic formulation, which is produced in AqVida’s new state-of-the-art injectable manufacturing facility located in Dassow, Germany. AqVida’s ultramodern robotic manufacturing line, designed for filling cytotoxic injectables, will be utilized to pro
Racketeering Lawsuit Filed by Boies Schiller Flexner LLP Alleges Czech Oligarch Defrauds US Hedge Fund and Former Partner Out of Over $1 Billion18.4.2019 07:41:00 CEST | Pressemelding
New York hedge fund, Kingstown Capital Management L.P, and other plaintiffs filed a lawsuit on 10 April 2019 in the Southern District of New York against Radovan Vitek, a Czech real estate mogul with business interests throughout Europe, whose fortune Forbes magazine estimates at $3.5 billion. Represented by litigation powerhouse Boies Schiller Flexner LLP, the hedge fund Kingstown Capital Management L.P and Czech investment firm Investhold Ltd allege that Vitek ran an elaborate criminal enterprise that defrauded the plaintiffs out of more than US $1 billion. According to the complaint, Berlin’s largest commercial real estate landlord, Vitek engaged in racketeering activity including wire fraud, mail fraud, money laundering, and other crimes and amassed his wealth at the expense of the plaintiffs, according to the complaint. His commercial interests span multiple jurisdictions including the Czech Republic, Switzerland, Luxembourg, Germany, Croatia and UK. The complaint alleges that Vit
MHI Thermal Systems Develops Demonstration Unit of the World’s First Small-Capacity Residential Air-Conditioner Adopting the Low-GWP R454C Refrigerant18.4.2019 07:21:00 CEST | Pressemelding
Premiering for the first time in the world, Mitsubishi Heavy Industries Thermal Systems, Ltd., a Group company of Mitsubishi Heavy Industries, Ltd. (MHI) (TOKYO: 7011), is adopting R454C, a refrigerant with an extremely low global warming potential (GWP), in a 1-horsepower (HP) class residential air-conditioner. The conventional shortcomings of the R454C,for example; inferior heat exchanger performance attributable to it being a mixed refrigerant have been overcome through the use of proprietary technology that optimize the heat exchanger’s flow volume and other measures. The company has already developed a demonstration unit of the residential air-conditioner featuring R454C and preparations are underway towards mass production with an eye on an initial launch into the European market, where environmental regulations are particularly stringent. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20190418005241/en/ Residential type
Hologic Receives European CE Mark for ThinPrep® Genesis Processor, an Automated Cytology Slide and Molecular Sample System18.4.2019 07:00:00 CEST | Pressemelding
Hologic, Inc. (Nasdaq: HOLX) announced today that the ThinPrep® Genesis processor for cytology slide and molecular test preparation has received a CE IVD mark in Europe. The system features increased automation capabilities, together with ergonomic and chain of custody benefits, compared to older instruments. Most importantly, the instrument will prepare slides for cytology as well as aliquot samples for molecular testing, reducing manual sample handling. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20190418005130/en/ ThinPrep Genesis processor (Photo: Business Wire) The Genesis processor is the latest extension of the ThinPrep portfolio, which revolutionized and increased the accuracy of cervical cancer screening with the first liquid-based Pap test in 1996. Hologic launched an updated ThinPrep® 2000 processor in 2017 and received FDA approval in 2018 for the ThinPrep® Integrated Imager, which guides cytotechnologists to ar
Ipsen Completes Acquisition of Clementia Pharmaceuticals18.4.2019 05:00:00 CEST | Pressemelding
Regulatory News: Ipsen (Euronext: IPN; ADR: IPSEY) and Clementia Pharmaceuticals (NASDAQ: CMTA) today announced the closing of Ipsen’s acquisition of Clementia following approval of the arrangement by Clementia shareholders and the Quebec Superior Court. Pursuant to the arrangement, Clementia shareholders will receive US$25.00 per share in cash upfront and one contingent value right (CVR) per share entitling them to receive US$6.00 per CVR upon the U.S. Food and Drug Administration's (FDA) acceptance of the regulatory filing for palovarotene for the treatment of multiple osteochondromas (MO). Clementia’s key late-stage clinical asset palovarotene is an investigational retinoic acid receptor gamma (RARγ) selective agonist, for the treatment of two rare bone disorders, fibrodysplasia ossificans progressiva (FOP) and multiple osteochondromas (MO), and other diseases. The palovarotene regulatory submission for the prevention of heterotopic ossification (HO) in patients with FOP in the U.S.
Sartorius Starts off Fiscal 2019 with a Strong First Quarter18.4.2019 05:00:00 CEST | Pressemelding
Sartorius, a leading international partner of biopharmaceutical research and the industry, started off fiscal 2019 with substantial double-digit growth in order intake, sales revenue and earnings. Consolidated first-quarter sales revenue rose in constant currencies by 16.8% to 435.7 million (reported: +19.4%); order intake increased 16.6% to 482.8 million euros (reported: +19.3%). Sartorius’ underlying EBITDA1) surged 28.7% to 114.0 million euros. Its respective underlying EBITDA margin for the first three months of 2019 was 26.2% (Q1 2018: 24.3%), with a good half a percentage point of this increase resulting from the change in accounting rules2), as expected. Relevant net profit3) for the Group climbed 30.8% to 48.6 million euros. Earnings per ordinary share were 0.71 euros (Q1 2018: 0.54 euros); earnings per preference share, 0.72 euros (Q1 2018: 0.55 euros). “We are very pleased with our first-quarter results,” said Dr. Joachim Kreuzburg, CEO and Executive Board Chairman. “In Biopr